

OCT 07 2010

US 10/555895, PCT/US2004/14368, EU Patent 1620024, Canadian Patent 2524443 & Others

CA 02524443 2007-10-02

64. The porous conduit of any one of claims 56 to 59, wherein said porous conduit has a plurality of protrusions extending therefrom.

65. The porous conduit of any one of claims 56 to 59, wherein said porous conduit is formed of a multi-filament portion and a mono-filament portion.

66. The porous conduit of any one of claims 56 to 59, wherein said porous conduit is formed of a biodegradable material.

67. The porous conduit of any one of claims 56 to 59, wherein said porous conduit is formed of a non-degradable material.

68. The porous conduit of any one of claims 56 to 67, wherein said porous conduit is porous and has a pore size of 200 microns to 10 nanometers.

69. The porous conduit of any one of claims 56 to 67, wherein said porous conduit has channels therethrough, said channels each having a diameter of 200 microns to 10 nanometers.

70. The porous conduit of any one of claims 56 to 69, further comprising a tube located around a central portion of said porous conduit.

71. The porous conduit of claim 70, wherein said tube is formed of a material chosen from the group of materials consisting of polytetrafluoroethylene, polypropylene, polyethylene, polyamide, polyester, polyurethane, silicon, poly-ether-ether-ketone, acetal resin, polysulfone, polycarbonate and polyethylene glycol.

72. The porous conduit of any one of claims 56 to 71, wherein at least a portion of said porous conduit is coated with fibrous tissue inhibitor.

73. A treatment kit used to provide immunoisolated retention of donor cells within a patient's intervertebral disc:

US 10/555895, PCT/US2004/14368, EU Patent 1620024, Canadian Patent 2524443 & Others

CA 02524443 2007-10-02

the porous conduit of any one of claims 56 to 72,
and donor cells injectable into the intervertebral disc.

74. The treatment kit of claim 73, wherein the donor cells are from a gland.

75. The treatment kit of claim 73, wherein the donor cells are from tissue.

76. The treatment kit of claim 73, wherein the donor cells have an origin chosen from the group of origins consisting of the pituitary gland, hypothalamus, adrenal gland, adrenal medulla, fat cells, thyroid, parathyroid, pancreas, testes, ovary, pineal gland, adrenal cortex, liver, renal cortex, kidney, thalamus, parathyroid gland, ovary, corpus luteum, placenta, small intestine, skin cells, stem cells, gene therapy, tissue engineering and cell culture.

77. The treatment kit of any one of claims 73 to 76, further comprising growth factor injectable into the intervertebral disc.

78. The treatment kit of any one of claims 73 to 77, wherein the donor cells are capable of creating a therapeutic product.

79. The treatment kit of any one of claims 73 to 77, wherein the donor cells are capable of creating a product chosen from the group of biosynthesized products consisting of adrenaline, adrenocorticotrophic hormone, aldosterone, androgens, angiotensinogen (angiotensin I and II), antidiuretic hormone, atrial-natriuretic peptide, calcitonin, calciferol, cholecalciferol, calcitriol, cholecystokinin, corticotropin-releasing hormone, cortisol, dehydroepiandrosterone, dopamine, endorphin, enkephalin, ergocalciferol, erythropoietin, follicle stimulating hormone, γ -aminobutyrate, gastrin, ghrelin, glucagon, glucocorticoids, gonadotropin-releasing hormone, growth hormone-releasing hormone, human chorionic gonadotrophin, human growth hormone, insulin, insulin-like growth factor, leptin, lipotropin, luteinizing hormone, melanocyte-stimulating hormone, melatonin, mineralocorticoids, neuropeptide Y, neurotransmitter, noradrenaline,

US 10/555895, PCT/US2004/14368, EU Patent 1620024, Canadian Patent 2524443 & Others

CA 02524443 2007-10-02

oestrogens, oxytocin, parathyroid hormone, peptide, pregnenolone, progesterone, prolactin, pro-opiomelanocortin, PYY-336, renin, secretin, somatostatin, testosterone, thrombopoietin, thyroid-stimulating hormone, thyrotropin-releasing hormone, thyroxine, triiodothyronine, trophic hormone, serotonin, and vasopressin.

80. Use of the deployment device of any one of claims 1 to 55 for deploying the porous conduit into intervertebral disc for re-establishing an exchange of nutrients and waste between an intervertebral disc and bodily circulation.

81. Use of the porous conduit of any one of claims 56 to 72 to halt or reverse degeneration of an intervertebral disc.

US 10/555895, PCT/US2004/14368, EU Patent 1620024, Canadian Patent 2524443 & OthersIssued Patents from PCT/US2004/014368

Australian patent 2004238302 on May 11, 2007

Canadian patent 2,524,443 on June 17, 2008

Chinese patent 200480012017.3 on November 21, 2007

EU patent 1620024 on April 4, 2007

Austrian patent 1620024

German patent 1620024

French patent 1620024

Irish patent 1620024

Italian patent 1620024

Spanish patent 1620024

Swiss patent 1620024

UK patent 1620024

Hong Kong patent HK1079081 on June 15, 2007

Indian patent 224914 on November 21, 2008

Mexican patent 258671 on July 11, 2008

New Zealand patent 543091 on September 12, 2007

South Africa 2005/8292 on December 27, 2006

Singapore patent 200506343-3 on October 31, 2007

Pending Patents from PCT/US2004/014368 as of October 7, 2010

Brazil patent application P10410425-0

Israel patent application 171168 (claims approved by examiner)

Japan Patent Application 2006-529365

Korea patent application 2005-7020723

US patent application 10/555,895